留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

CYP2C19基因多态性对药物代谢影响的研究进展

彭净,  刘卫

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 508-512
彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
引用本文: 彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
shu
PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
Citation: PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
shu

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008
  • 1.

    解放军88医院, 山东 泰安 271000;济宁医学院附属医院, 山东 济宁 272000

  • 2.

    解放军88医院, 山东 泰安 271000

基金项目: 山东省药学会奥赛康中青年临床药师资助项目(No.sdpa-ask-2013-02)

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

  • 1.

    No. 88 Hospital of PLA, Taian 271000, China;Affiliated Hospital of Jining Medical University, Ji'ning 272000, China

  • 2.

    No. 88 Hospital of PLA, Taian 271000, China

  • 摘要: 药物代谢和相互作用的差异与CYP的单核苷酸基因多态性有关。综述CYP2C19基因多态性对质子泵抑制剂、抗真菌药伏立康唑、抗血小板药氯吡格雷的代谢和药物相互作用的影响,以期为个体化用药提供参考。
    Abstract: Drug metabolism and drug-drug interactions were associated with the single nucleotide polymorphisms of CYP. The relationship between CYP2C19 polymorphisms and metabolism as well as interactions of proton pump inhibitors, voriconazole and clopidogrel were reviewed to provide evidence for personalized medication.
  • [1] 吴敏良,吴晓虹,陈枢青. 细胞色素P4502C19 在中国汉族人群不同组织中的分布差异研究[J] .中国药学杂志,2005,40(3):215-218.
    [2] Bertilsson L,Lou YC, Du YU,et al.Pronounced difference between native Chinese and Swedish populations in the polymorphichydroxylation of debrisoquin and S-mephenytoin[J]. Clin Pharmacol Ther, 1992,51(4):388-397.
    [3] Blaisdell J,Mohrenweiser H,Jackson J,et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J]. Pharmacogenetics, 2002,12(9):703-711.
    [4] Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J] . Clin Pharmacol Ther,2006,79(1):103-113.
    [5] Xie HG,Huang SL,Xu ZH,et al.Evidence for the effect of gender on activity of S-mephenytoin in a Chinese population[J]. Pharmacogenetics, 1997,7(2):115-119.
    [6] Wedlund PJ,Aslanian WS,McAllister CB,et al.Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism [J]. Clin Pharmacol Ther,1984,36(6):773-780.
    [7] Jacquehnes SM, PhamlJ DB, John WF.Determination of CYP2C19 phenotype in black Americans wit homeprazole: correlation with genotype [J]. Clin Pharmacol Ther,1996,60(2):138-144.
    [8] Zhang YX, Wei SJ, Yang XY,et al. Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2014,52(10):850-855.
    [9] 姜英杰,李瑜元, 聂玉强, 等. 雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19 基因多态性的关系[J]. 广州医学院学报, 2004, 32(3): 22-25.
    [10] Sezgin O,Barlas IO,Uçbilek E,et al.Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective[J].Acta Gastroenterol Belg,2014,77(1):3-7.
    [11] Lee JY,Kim N,Kim MS,et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance[J]. Dig Dis Sci,2014,59(6):1235-1243.
    [12] John J,Lima,Jason EL,et al.Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children[J]. Pediatry,2013,163(3):686-691.[13] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not rasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
    [13] Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015,65(6):494-500.
    [14] 谢 婧,杨莉萍,刘 瑶,等.CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J]. 中国药房,2012,23(28):2618-2621.
    [15] Crepeau AZ, Moseley BD, Wirrell EC.Specific safety and tolerability considerations in the use of anticonvulsant medications in children[J].Drug Health Patient Saf,2012,4: 39-54.
    [16] Kouga T, Shimbo H, Iai M,et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev, 2015,37(2):243-249.
    [17] de Leon J.The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19[J].Clin Psychopharm,2007,27(3):241-245.
    [18] 王瓅珏,唐惠林,段京莉. CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J]. 中国临床药理学杂志,2011,29(8):607-611.
    [19] Zonios D,Yamazaki H,Murayama N,et al.Voriconazole metabolism, toxicity and the effect of cytochrome P450 2C19 genotype [J].J Infect Dis,2014,209(12):1941-1948.
    [20] Choi CI,Bae JW,Lee YJ,et al.Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics[J]. J Clin Psychopharmacol, 2014,34(1):139-142.[22] Nastasi-Catanese JA,Padilla-Gutiérrez JR,Valle Y, et al.Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response[J]. Genet Mol Res,2013,12(4):4413-4421.
    [21] Sibbing D,Morath T,Stegherr J,et al.Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101(4):714-719.
    [22] Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor[J].Arch Intern Med, 2010,170(8):704-710.[25] 曲彩红,黎小妍. 伏立康唑与奥美拉唑可能的不良相互作用致肌病及肝功能恶化[J]. 药物不良反应杂志,2011,13(6): 374-377.
    [23] Kim DY,Park HJ,Lee YJ.Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections[J]. Int J Clin Pharmacol Ther,2014,52(3):209-216.
    [24] Simon T, Steg PG, Gilard M, et al.Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute st-elevation and non-st-elevation myocardial infarction (FAST-MI) registry[J]. Circulation,2011,123(5):474-482.
    [25] Furuta T,Iwaki T,Umemura K. Influences of different proton pump inhibitors on the antiplatelet function of clopidogrel in relation to CYP2C19 genotypes[J] . Br J Clin Pharmacol, 2010, 70(3):383-392.
    [26] Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) [J].JACC Cardiovasc Interv,2011,4(4):392-402.
    [27] Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
    [28] Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation,2009, 119(9):2553-2560.
    [29] Erlinge D,James S,Duvvuru S,et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J].Thromb Haemost,2014,111(5):943-950.
  • [1] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [2] 迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛.  负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
    [3] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [4] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [5] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [6] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [7] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [8] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [9] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [10] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [11] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [12] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [13] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [14] 姚瑞阳, 于海征, 李耀盺, 张磊.  丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
    [15] 杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯.  瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
    [16] 刘汝雄, 杨万镇, 涂杰, 盛春泉.  铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
    [17] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
    [18] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3803
  • HTML全文浏览量:  422
  • PDF下载量:  277
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-05-16
  • 修回日期:  2015-01-20

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008
  • 1. 解放军88医院, 山东 泰安 271000;济宁医学院附属医院, 山东 济宁 272000
  • 2. 解放军88医院, 山东 泰安 271000
    • 基金项目:  山东省药学会奥赛康中青年临床药师资助项目(No.sdpa-ask-2013-02)
  • 收稿日期: 2014-05-16
  • 修回日期: 2015-01-20

摘要: 药物代谢和相互作用的差异与CYP的单核苷酸基因多态性有关。综述CYP2C19基因多态性对质子泵抑制剂、抗真菌药伏立康唑、抗血小板药氯吡格雷的代谢和药物相互作用的影响,以期为个体化用药提供参考。

English Abstract

彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
引用本文: 彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
shu
PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
Citation: PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
shu

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计